Strategies for dsRNA Removal and Accurate Quantitation in Emerging mRNA Modalities
Register Now Panelists:
Nathaniel Clark, PhD Senior ScientistRepligen View Bio
Panelist ...
New method brings hope for personalized treatment of inflammatory bowel disease
Patients with inflammatory bowel disease often have to wait a long time to find the right medicine. But the methods of a large interdisciplinary research team offer hope.
IBD is the common abbreviation for inflammatory...
Macrophage-Blocking Antibodies Help Overcome Breast Cancer Endocrine Resistance
Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer can tackle tumors...
Ginkgo Bioworks Awarded Project Agreement Through BARDA’s BioMaP-Consortium
Ginkgo Bioworks has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The goal of the project, which has a total contract value of up...
The Pursuit of an Optimal Diagnostic Strategy
Sponsored content brought to you by
Precision oncology is reshaping cancer care, with genomics increasingly guiding diagnosis and therapeutic decisions. At the heart of this transformation are companion diagnostics (CDx), essential tools to ensure patients...
Researchers use genetic engineering to create “product-ready” snakebite antivenom
An international team of researchers has used genetic engineering to create the first ever “product-ready” antivenom for snakes such as cobras and mambas.
The groundbreaking research is published in Nature by a team led by the Technical...
Study reveals how “P bodies” heavily influence a cell’s fate
How do stem cells know what to become? Nearly three decades after scientists isolated the first human embryonic stem cells, researchers are still working hard to understand precisely how a single, undifferentiated cell can...
Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia...
Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has signed a partnership with Solve Scientific Australia, a...
StockWatch: Intellia Shares Sink as Clinical Hold Follows Safety Setback
John Leonard, MD, Intellia Therapeutics president and CEO
Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John Leonard, MD, announced that, given greater-than-expected patient enrollment in a Phase III trial assessing nexiguran...
Bird Flu’s Human Risk Spurs Phage Therapy Research
Highly pathogenic avian influenza A (H5N1, commonly known as HPAI or bird flu) is a formidable worldwide public health concern. With approximately a 100% mortality rate, the World Organization for Animal Health estimates that...
